T-REX has quite a generous NI margin: Non-inferiority is declared if the de-escalation arm is not more than 4.5 percentage points worse than standard regional RT. This corresponds to an HR of about 1.41, assuming 88% 5-year RFS with standard treatment. #OncTwitter#BCSM#ASCO26
#ESTRO26@cancerphysicist APHRODITE trial: EDRT (62Gy SIB) boosted 6-mo cCR to 49.4% vs 33.3% with SDRT in early rectal cancer (+16%; OR 2.27, p=0.038). First RCT evidence for dose escalation benefit + low toxicity!
This is a great thread about OLIGOMA.
I would just add that we can't expect phase III data for each histology. Two large histology-specific phase III trials (HN and esophagus) just closed due to poor accrual.
For SABR-COMET the strongest predictor of accrual was the level of equipoise of the referring physicians. Sometimes the referring physicians do not support randomization, which makes it difficult for us to do so.
https://t.co/EFDLruns2W
JCOG 1208 is a nice study of ENI dose (46 Gy/23 fx) and volume reduction, without any solitary elective neck failures; another trial that supports ENI de-intensification.
However, we cannot be satisfied with 79% locoregional PFS, especially for oropharyngeal cancer.
Even with T1-2 N0-1 disease, sometimes concurrent chemotherapy may be needed.
1/7 🧵 New in @LancetOncology: we built a Delphi consensus on primary endpoints for MDT trials in oligometastatic cancer — because the endpoints we've been using were designed for drugs, not for ablation.
On behalf of the EORTC–ESTRO OligoCare consortium.
@DawnsMission Needle biopsies are standard because knowing exactly what you’re treating overwhelmingly outweighs the exceedingly small risks. Major reviews do not show increased metastasis from routine biopsy. Fear-based misinformation harms real patients.
Say hello to Srón! It's our new 3D-printed head for teaching nasopharyngoscopy.
(Srón means nose in Irish, pronounced "shrone")
You can print Srón yourself for free, or order one from us, at https://t.co/HJYfyrHXVk
Very honoured to have taken part on this long endeavour covering so many topics led by @cancerphysicist and @71Rianne . It was truly a learning experience!
📗 Just published in the @RO_GreenJournal: ESTRO technical #guideline: intensity modulated radiotherapy and image guided radiotherapy for #rectalcancer
👉 Read the abstract: https://t.co/eHVTtTgxfu
#IMRT#IGRT
The Olympic drone pilots are the best thing that happened the games, unsung heroes, period.
The coverage this year is officially on another level. We can finally feel so much closer to the action, it's pure magic, unreal.
Is it just me, or is this the best upgrade in years?
@DrewMoghanaki Birds of a feather, flock together.
Or we are whom we spend time with.
If we are in bubbles, we only hear our own ideas. We need to get our voices out there to our neighbouring specialities.
🚀 MDT in oligometastatic #ProstateCancer 🚀
👉WOLVERINE IPD meta-analysis in @TheLancetOncol
🧪 7 randomized trials, 574 pts
📉 MDT → ↓ progression, ↓ radiographic progression, ↓ time to CRPC
🔁 Consistent benefit across SOC (obs, ADT, ARPI)
🛡️ Low toxicity, short treatment courses
⚖️ OS not definitive; but this is the strongest evidence yet to integrate MDT
👏 @ChadTangMD@piet_ost
🔗 to study https://t.co/OtIHw4RGgV
🔗 to editorial https://t.co/aeWi3Wx0ms
@PCFnews@urotoday@UrologyTimes
Update on European Citizens’ Initiatives:
🔹 “Stop Destroying Videogames” has reached the required threshold and is now under Commission examination
🔹 Explore all officially registered initiatives, including the newest one from this week.
More: https://t.co/Mdn36U8xi0